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Abstract
Objective: A systematic review of randomized controlled trials (RCTs) was conducted to evaluate the efficacy of
pregabalin for the management of postoperative pain in patients undergoing primary total knee arthroplasty (TKA)
and primary total hip arthroplasty (THA).
Method: The PubMed, Embase, Cochrane Central Register of Controlled Trials, and Google Scholar databases were
searched for related articles using search strategy. RevMan 5.3 software was selected to conduct the meta-analysis.
Results: Seven RCTs were included in our meta-analysis. There were significant differences in visual analogue scale
(VAS) at 24 and 48 h with rest, knee flexion degree, mean morphine consumption, and postoperative side effects
(nausea, vomiting, pruritus, and dizziness) when comparing the pregabalin group to the placebo group after TKA
and THA. However, the differences in VAS at 72 h with rest and at 24 h on movement were not significant
between the two groups.
Conclusions: Pregabalin was found to improve pain control at 24 and 48 h with rest, reduce morphine
consumption, improve the knee flexion degree, decrease the incident rate of nausea, vomiting, and pruritus, and
increase the incident rate of dizziness after TKA and THA but could not improve the pain control at 72 h with rest.
In summary, the use of pregabalin may be a valuable asset in pain management within the first 48 h after TKA and
THA. However, future studies regarding doses and pregabalin medication are required.
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Background
Total knee arthroplasty (TKA) and total hip arthroplasty
(THA) have become common treatments for patients
with severe knee and hip functional impairment. These
surgeries can significantly relieve pain, restore joint
function, and improve quality of life [1, 2]. The number
of patients undergoing TKA and THA has increased
steadily each year, and this trend will continue in the
foreseeable future due to the aging of the population [3].
Postoperative pain after total joint arthroplasty has
remained a serious problem, which prolongs length of
hospital stay and functional recovery. Therefore, appro-
priate pain management protocol is necessary to relieve
postoperative pain and achieve early functional recovery.
Opioids have generally been used for pain control after
TKA or THA. However, common side effects, such as
sedation, dizziness, nausea, vomiting, constipation, phys-
ical dependence, tolerance, and respiratory depression,
are serious problems with these medications [4, 5]. Preg-
abalin is a structural analog of γ-aminobutyric acid
(GABA) that acts on the α2δ subunit of voltage-
dependent calcium channels, which can reduce the re-
lease of neurotransmitters [6–8]. Although it was
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approved for the treatment of partial seizures, pregabalin
has been administered for other indications, such as
fibromyalgia, diabetic neuropathy, and even acute post-
surgical pain [9].
In recent years, some randomized controlled trials
(RCTs) have been carried out to evaluate the effects
of pregabalin. However, different conclusions have
been reached, and the efficacy of pregabalin for pain
management among TKA and THA patients has
remained unclear. Jain et al. [10] reported that peri-
operative administration of pregabalin reduced opioid
consumption, improved postoperative analgesia, and
yielded higher patient satisfaction levels in primary
TKA. However, Singla et al. [11] showed that there
was no significant difference between pregabalin and
placebo with respect to the worst pain (24/48 h post-
surgery) after TKA. Similar conclusions have been
reached by YaDeau [12]. Therefore, the role of prega-
balin for pain control and functional recovery after
TKA and THA has not been investigated in system-
atic review and meta-analysis. This meta-analysis was
conducted to determine whether pregabalin used sys-
tematically can decrease postoperative pain and im-
prove joint function when compared with placebo.
Materials and method
Search strategy
The PubMed (1980–July 2016), Embase (1980–July
2015), Cochrane Central Register of Controlled Trials,
and Google Scholar databases were searched for related
articles using the search strategy outlined in Appendix 1.
According to the Cochrane Collaboration guidelines, we
also conducted other database searches. The search
strategy is presented in Fig. 1.
Study selection
Included studies were considered eligible if they met the
following criteria:
Study design: Interventional studies
Population: Patients were scheduled for primary TKA
and THA
Intervention: Pregabalin
Comparator: Placebo or nothing
Outcome:
Primary outcome: Visual analogue scale (VAS) at 24,
48, and 72 h with rest and at 24 h on movement and
morphine consumption
Secondary outcome: Knee flexion degree and treatment
side effects (nausea, vomits, pruritus and dizziness)
Quality assessment
Published RCTs comparing pregabalin with a control
(placebo or nothing) in patients who underwent primary
TKA or THA are included in this meta-analysis. The eli-
gibility assessment was conducted by two reviewers (F.L.
and JX.M.) independently in an unblended standardized
manner. Disagreements were resolved by consensus. Ac-
cording to the Cochrane Handbook for Systematic Re-
views of Interventions [13], the methodological quality
and risk basis of the included studies were evaluated as
Fig. 1 Search results and selection procedure
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follows: (1) randomization method, (2) allocation con-
cealment, (3) blind method of participant and outcome
assessment, and (4) complete outcome data. The risk of
bias can be seen in Figs. 2 and 3.
Data extraction
Data were extracted from the enrolled studies by two
authors independently. The extracted data included
publication data, title, first author’s name, patient demo-
graphics, sample size, morphine consumption, pain
scores, knee flexion degree, postoperative complications,
and side effects (nausea, vomiting, pruritus, and
dizziness).
Data analysis and statistical methods
The data were analyzed by Review Manager Software for
Windows (RevMan Version 5.3, Copenhagen; The Nordic
Cochrane Center, The Cochrane Collaboration, 2014). The
means and standard deviations were applied to assess con-
tinuous variable outcomes with a 95% confidence interval
(CI), and relative risks and 95% CIs were applied to assess
dichotomous outcomes. Statistical heterogeneity was tested
using the I2 value and chi-squared test. A P value <0.05 was
considered statistically significant, and the random effect
model was used for analysis. If P values were <0.05 or I2 >




A total of 123 relevant articles were identified in the data-
bases. Seven RCTs were included by reading the abstracts
and entire article in detail. The overall methodological qual-
ity of the included studies was relatively high. All of the
RCTs applied randomized, placebo-controlled, and double-
blind strategies, which reflected the high quality of the in-
cluded literature. Baseline data were provided in all in-
cluded studies without providing the intention to treat
analysis. Finally, 823 patients were included in our meta-
analysis. The patient characteristics are presented in Table 1.
The sample sizes for each study ranged from 40 to 216.
Randomization was stated in all RCTs through a
computer-assisted program, and all of the RCTs used a
double-blind methodology. Four studies [10–12, 14]
were for TKA, while another three studies [15–17]
were for THA, and there were 510 patients for TKA
and 313 patients for THA. All of the articles had been
published since 2008, and four of the articles had been
published in the last 3 years. In experimental groups,
Fig. 2 Risk of bias graph
Fig. 3 Risk of bias summary
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each patient received pregabalin for corresponding dos-
age 1–2 h before surgery, and patients received prega-
balin with dosages ranging from 150 to 300 mg orally
in the postoperative days. One TKA study used a dos-
age of 150 mg pregabalin every day after surgery, and
three studies used a 300 mg dosage. YaDeau [12] con-
ducted a multidose trial in which the dosage of prega-
balin was 0, 100, 200, and 300 mg for each group every
day. In this meta-analysis, we use the data of the
300 mg as the experimental group and that of the 0 mg
as the control group. Singla [11] conducted a multicen-
ter, randomized, double-blind, placebo-controlled trial;
one part of the study was for TKA, two dosages (150,
300 mg/d) were included, and we used the 300 mg dos-
age for our meta-analysis. For THA studies, two studies
used 150 mg/d pregabalin for the experimental group,
and one study used 300 mg/d. Postoperative analgesia
included patient-controlled analgesia/patient-controlled
epidural analgesia (PCA/PCEA), celecoxib, acetamino-
phen, non-steroidal anti-inflammatory drugs, and mor-




Based on six studies providing available data, we
found that there was significant heterogeneity (χ2 =
43.57, df = 5, P < 0.00001, I2 = 89%). As depicted in
Fig. 3, the pooled results produced a better outcome
between the two groups according to a random ef-
fects model (MD = −15.92, 95% CI, [−26.56−5.29], P =
0.003, Fig. 4). A subgroup analysis was performed for
the morphine consumption (Table 2).












Buvanendran et al. [14] 106/110 64/63 29/36 300 RCT PCEA + celecoxib 200 mg bid for 3 days while in the
hospital
Jain et al. [10] 20/20 60/57 9/5 150 RCT PCEA (containing bupivacaine 0.0625% and morphine
0.05 mg/ml)
Singla et al. [11] 96/98 64/63 35/44 300 RCT PCA (morphine) + oral analgesia 5 mg hydrocodone
bitartrate/500 mg acetaminophen tablets every 4–6 h
YaDeau et al. [12] 30/30 68/66 7/16 300 RCT PCEA (morphine) + meloxicam 5 mg and oxycodone
paracetamol 325 mg
Mathiesen et al. [15] 40/38 67/66 14/18 300 RCT PCA (morphine) + acetaminophen 1 g tid
Clarke et al. [16] 83/79 60/60 41/41 150 RCT PCA (morphine) for 24 h + celecoxib 200 mg bid,
oxycontin 5 mg tid
Martinez et al. [17] 35/38 64/64 20/25 150 RCT PCA for 48 h, then paracetamol, non-steroidal anti-
inflammatory drugs and oral opioid
Pre/P pregabalin/placebo, QAS quality assessment score, RCT randomized controlled trial, PCT prospective control trials
Fig. 4 The effect of pregabalin illustrated by a forest plot diagram on mean morphine consumption
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VAS score at rest
VAS at 24 h
A total of four component studies with 417 patients pro-
vided a VAS score at 24 h after surgery with rest. Our
meta-analysis revealed that pregabalin produced a better
outcome compared to the control group with rest at
24 h in terms of VAS score (MD = −0.66, 95% CI
[−1.28–0.04], P = 0.04, Fig. 5). We used a random effect
model because statistical heterogeneity was high (χ2 =
14.59, df = 3, P = 0.002, I2 = 79%).
VAS at 48 h
Only three studies with 275 patients reported the VAS
score at 48 h postoperatively. Our meta-analysis found
a highly significant difference between the two groups
(MD = −0.95, 95% CI, [−1.27–0.64], P < 0.00001, Fig. 6).
A fixed-effect model was preferred because the statis-
tical heterogeneity was low (χ2 = 0.28, df = 2, P = 0.87,
I2 = 0%).
VAS at 72 h
Three studies stated the VAS score at 72 h postopera-
tively with rest, and our meta-analysis revealed that
there was no significant difference between the two
groups (MD = −0.56, 95% CI, [−1.42–0.31], P = 0.21,
Fig.7). We used a random effect model because of the
significant statistical heterogeneity (χ2 = 7.26, df = 2, P =
0.03, I2 = 72%).
VAS on movement
Four studies in our meta-analysis reported the VAS score
on movement at 24 h, and the available data demonstrated
that there was no significant difference between the two
groups (MD= −0.54, 95% CI, [−1.23–0.15], P = 0.13,
Fig. 8). The pooled results showed significant heterogen-
eity (χ2 = 6.91, df = 3, P = 0.07, I2 = 57%), and therefore, a
random effect model was used.
Knee flexion degree
Only two studies [11, 14] provided the data of knee
flexion degree measured at 24, 48, and 72 h, respectively.
The results demonstrated that there were significant dif-
ferences between the two groups in TKA patients (MD
= 4.89, 95% CI, [3.41, 6.37], P < 0.00001, Fig. 9). There
was significant heterogeneity between the two groups
based on the pooled data (χ2 = 11.39, df = 5, P = 0.04, I2
= 56%), so we used a random effect model.
Side effect
We summarized four side effects of pregabalin after
TKA and THA (Fig. 10). The results are presented in
Table 3.
Discussion
This meta-analysis was performed to systematically re-
view the literature and form a comprehensive under-
standing of the efficacy of pregabalin for the
management of postoperative pain after TKA or THA.
Our results indicated that the pregabalin played an im-
portant role in the VAS with rest at 24 and 48 h, knee
flexion degree, morphine consumption, and adverse
events. No statistically significant differences were found
in the VAS score with rest at 72 h and VAS on move-
ment at 24 h between the pregabalin group and the con-
trol group.





χ2 MD and 95% CI I2(%) P
TKA 3 0.34 −3.64(–5.04,−2.25) 0 0.84
THA 3 7.94 −22.90(−34.07,−11.74) 75 0.02
Fig. 5 The effect of pregabalin illustrated by a forest plot diagram on 24 h VAS at rest
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Mean morphine consumption was one of the primary
outcomes in our study. Six studies documented mean
morphine consumption, and significant difference was
found between the pregabalin group and the control
group in our meta-analysis (P < 0.003). We converted
opioid use to morphine equivalents in all studies because
different opioid drugs and units of measurement were
used to record opioid consumption. It was very import-
ant to reduce opioid consumption after surgery because
some patients would be easily addicted to opioid medi-
cations used after TKA or THA [18]. Our pooled data
showed that pregabalin could decrease postoperative
opioid consumption. This result agrees with those of
other studies examining the administration of pregabalin
[10, 14, 19]. Another meta-analysis showed that pregaba-
lin can reduce 24-h morphine consumption in gyneco-
logic, laparoscopic cholecystectomy, orthopedic, spine,
and miscellaneous procedures [20]. These outcomes in-
dicate that ideal analgesic effects can be achieved with
less morphine consumption when pregabalin is used
simultaneously.
The VAS pain score was a useful indicator for the as-
sessment of pain with high value. A 10-cm-long move-
able ruler was used to test the pain level for patients
after TKA or THA (0–10, 0 was no pain and 10 was un-
bearable pain). In our study, 24, 48, and 72 h at rest and
24 h of movement postoperatively were selected as the
point-in-time for comparison. This meta-analysis
showed significant difference between 24 and 48 h VAS
scores at rest, which indicates that pregabalin can effect-
ively relieve postoperative pain at rest. Jokela et al. [21]
found that premedication with 75 or 150 mg pregabalin
significantly reduced the VAS score for postoperative
pain at 24 h after laparoscopic gynecologic surgery (P <
0.05) when compared with diazepam 5 mg. Some other
studies [22, 23] have reported that pregabalin adminis-
tration could reduce the VAS score at 24 h compared
with placebo postoperatively. Gianesello [24] showed
Fig. 6 The effect of pregabalin illustrated by a forest plot diagram on 48 h VAS at rest
Fig. 7 The effect of pregabalin illustrated by a forest plot diagram on 72 h VAS at rest
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that perioperative administration of pregabalin at a dose
of 300 mg every day resulted in a significant reduction
in VAS scores at 48 h postoperatively for patients under-
going major spinal surgery. These outcomes demon-
strate that administration of pregabalin could reduce
VAS score at 24 and 48 h with rest after surgery. The
VAS at 72 h with rest postoperatively was not significant
in our pooled data. The decreased benefits of pregabalin
on pain during movement could be explained by the
short mean elimination half-life of pregabalin [25]. No
significant difference was found in VAS on movement at
24 h, and the result was similar to another meta-analysis
of pregabalin for tonsillectomy [26]. One explanation for
this could be that the movement of body intensified the
pain after surgery. Additionally, the sample size was
small, with only four included studies. Therefore, we
could not determine the effect of pregabalin for TKA
and THA at 24 h of movement postoperatively. Al-
though no significant reduction in VAS score at 72 h
with rest and at 24 h on movement postoperatively, the
score of the pregabalin group was lower than that of the
control group in most studies. In summary, preoperative
administration of pregabalin could improve acute pain
control after TKA and THA.
Knee flexion degree was a valuable indicator to evalu-
ate the motion of knee joints and functional recovery
Fig. 8 The effect of pregabalin illustrated by a forest plot diagram with 24 h VAS on movement
Fig. 9 The effect of pregabalin illustrated by a forest plot diagram on knee flexion degree
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[27, 28]. We established a subgroup to investigate the
reasons of heterogeneity and the data of different time
periods. Our pooled data showed that the pregabalin
groups can enhance the knee range of motion effectively
(P < 0.00001). Buvanendran [14] demonstrated that preg-
abalin shortened the time to achieve normal knee range
of motion (ROM). He thought this beneficial effect on
knee functions at the time of discharge facilitated nearly
full functionality. Pregabalin was shown to improve pain
control, and less pain can lead to more extensive activ-
ities, which may be the reason for the improvement of
knee function. Singla [11] showed that passive knee
range of motion for the operated knee was greater for
the 300 mg/d pregabalin group compared with placebo
Fig. 10 The effect of pregabalin illustrated by a forest plot diagram on side effects (nausea, vomiting, pruritus, and dizziness)
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at 24, 72, 96, 120 h, and at week 4 post-TKA, and active
ROM (upon flexion) was significantly greater in the
300 mg/d pregabalin group compared with that of the
placebo only group at week 4. Thus, according to this
result, we concluded that perioperative pregabalin con-
sumption had beneficial effects on improving knee
function.
Postoperative nausea and vomiting were usually
caused by different anesthetic modes that were mostly
related to the gastrointestinal system [29]. Our pooled
data showed that postoperative oral pregabalin could de-
crease the incidence of nausea and vomiting. The same
results were reported in another meta-analysis [30],
which indicated that preoperative pregabalin is associ-
ated with a significant reduction of postoperative nausea
and vomiting. Based on these outcomes, postoperative
administration of pregabalin has been shown to reduce
nausea and vomiting. Pruritus is another side effect dur-
ing the administration of pregabalin. As shown in Fig. 10,
pregabalin can significantly decrease the incident rate of
postoperative pruritus. Şavk [31] suggested that pregaba-
lin at a daily dose of 150 mg was effective in reducing
chronic pruritus. Dizziness was the most common ad-
verse effect profile of pregabalin. The pooled data
showed that the pregabalin would increase the incident
rate of dizziness. Griffin [32] reported that dizziness, fa-
tigue, and somnolence were among the most common
adverse effects of pregabalin. In summary, we found that
pregabalin can effectively reduce the incidence of nau-
sea, vomiting, and pruritus, but it can increase the inci-
dence of dizziness.
Our meta-analysis has the following potential limita-
tions: (1) only seven RCTs were selected in our meta-
analysis; if more studies were included, statistical efficacy
would increase. (2) The follow-up period of patients was
too short in some of the trials. Most patients were
followed up only in the short term. This may have re-
sulted in underreporting of some useful information. (3)
There were not sufficient data, such as neuropathic pain,
sleep disturbance, time to discharge, and physical com-
posite score above. (4) Risk of bias cannot be avoided in
this meta-analysis because only English publications
were included. (5) Almost all the included studies were
published by anesthetists, and some important details
usually considered by orthopedics, such as surgical
approach, methods of fixation, technique of incision,
and type of implant were not reported in those papers.
It is believed that all of these factors have the ability to
change the degree of postoperative pain, and that they
need to be taken into account in future studies.
Although this study has several limitations, it is the
first systematic review to evaluate the efficacy of prega-
balin with placebo in primary TKA and THA. Available
articles were screened strictly; hence, the articles
adopted for the final review were of high quality. How-
ever, more high-quality literature should be included to
elevate statistical efficacy and increase sample size.
Conclusions
Our meta-analysis indicated that pregabalin could im-
prove pain control at 24 and 48 h with rest, reduce mor-
phine consumption, and improve the knee flexion
degree as well as decreasing the incident rate of nausea,
vomiting, and pruritus and increasing the incident rate
of dizziness after TKA and THA but could not improve
the pain control at 72 h with rest. In summary, the use
of pregabalin may be a valuable asset in pain manage-
ment within first 48 h after TKA and THA. However, fu-
ture studies regarding doses and pregabalin medication
are required.
Appendix 1
#1 Total Knee Replacement
#2 Total Knee Arthroplasty
#3 “Arthroplasty, Replacement, Knee” [Mesh]
#4 Search (#1 OR #2) OR #3
#5 Total Hip Replacement
#6 Total Hip Arthroplasty
#7 “Arthroplasty, Replacement, Hip” [Mesh]
#8 Search (#5 OR #6) OR #7
#9 Search (#4 OR #8)
#10“Pregabalin” [Mesh]
#11 random*
#12 “Randomized Controlled Trial” [Publication Type]
#13 “Randomized Controlled Trials as Topic” [Mesh]
#14 Search (#11 OR #12 OR #13)
#15 Search (#9 AND #10 AND # 14)
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Table 3 Results of side effect
Outcome Studies Overall effect Heterogeneity
Effect estimate 95% CI P value I2 (%) P value
Nausea 6 0.55 0.37, 0.80 0.002 0 0.57
Vomits 5 0.53 0.33, 0.83 0.006 46 0.11
Pruritus 4 0.52 0.29, 0.95 0.03 0 1.0
Dizziness 4 1.95 1.19, 3.18 0.008 0 0.75
Li et al. Journal of Orthopaedic Surgery and Research  (2017) 12:49 Page 9 of 10
Availability of data and materials
As this paper is a meta-analysis, there are no patient datasets, and all the raw
data can be seen in the included figures.
Authors’ contributions
X-LM designed the study and proofread the manuscript. FL, JM, and MK
conceived of and designed the study, collected and analyzed the data, and
wrote the paper. XJ and YW collected and analyzed the data. LS, XZ, and BL
revised the draft and generated the figures. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no conflict of interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate




1Biomechanics Labs of Orthopaedics Institute, Tianjin Hospital, Tianjin
300050, People’s Republic of China. 2Tianjin Medical University, Tianjin
300070, People’s Republic of China.
Received: 29 September 2016 Accepted: 9 February 2017
References
1. Kahn TL, Soheili A, Schwarzkopf R. Outcomes of total knee arthroplasty in
relation to preoperative patient-reported and radiographic measures: data
from the osteoarthritis initiative. Geriatr Orthop Surg Rehabil. 2013;4(4):117–26.
2. Alshryda S, et al. A systematic review and meta-analysis of the topical
administration of tranexamic acid in total hip and knee replacement. Bone
Joint J. 2014;96-B(8):1005–15.
3. Bashinskaya B, et al. Arthroplasty utilization in the United States is predicted
by age-specific population groups. ISRN Orthop. 2012;2012.
4. Benyamin R, et al. Opioid complications and side effects. Pain Physician.
2008;11(2 Suppl):S105–20.
5. Kehlet H, Dahl JB. The value of “multimodal” or “balanced analgesia” in
postoperative pain treatment. Anesth Analg. 1993;77(5):1048–56.
6. Gray P. Pregabalin in the management of central neuropathic pain. Expert
Opin Pharmacother. 2007;8(17):3035–41.
7. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of
recent guidelines. Am J Med. 2009;122(10 Suppl):S22–32.
8. Li Z, et al. Pregabalin is a potent and selective ligand for α2δ-1 and α2δ-2
calcium channel subunits. Eur J Pharmacol. 2011;667(1–3):80–90.
9. Ryvlin P, Perucca E, Rheims S. Pregabalin for the management of partial
epilepsy. Neuropsychiatr Dis Treat. 2008;4(6):1211–24.
10. Jain P, et al. Evaluation of efficacy of oral pregabalin in reducing
postoperative pain in patients undergoing total knee arthroplasty. Indian J
Orthop. 2012;46(6):646–52.
11. Singla NK, et al. Pregabalin for the treatment of postoperative pain: results from
three controlled trials using different surgical models. J Pain Res. 2015;8:9–20.
12. YaDeau JT, et al. Pregabalin and pain after total knee arthroplasty: a double-
blind, randomized, placebo-controlled, multidose trial. Br J Anaesth. 2015;
115(2):285–93.
13. Wang T, et al. Analysis of risk factors for femoral head necrosis after internal
fixation in femoral neck fractures. Orthopedics. 2014;37(12):e1117–23.
14. Buvanendran A, et al. Perioperative oral pregabalin reduces chronic pain
after total knee arthroplasty: a prospective, randomized, controlled trial.
Anesth Analg. 2010;110(1):199–207.
15. Mathiesen O, et al. Pregabalin and dexamethasone for postoperative pain
control: a randomized controlled study in hip arthroplasty. Br J Anaesth.
2008;101(4):535–41.
16. Clarke H, et al. Pregabalin reduces postoperative opioid consumption and pain
for 1 week after hospital discharge, but does not affect function at 6 weeks or
3 months after total hip arthroplasty. Br J Anaesth. 2015;115(6):903–11.
17. Martinez V, et al. The analgesic efficiency of combined pregabalin and
ketamine for total hip arthroplasty: a randomised, double-blind, controlled
study. Anaesthesia. 2014;69(1):46–52.
18. Prommer E, Ficek B. Management of pain in the elderly at the end of life.
Drugs Aging. 2012;29(4):285–305.
19. Sawan H, et al. Pregabalin reduces opioid consumption and improves
outcome in chronic pain patients undergoing total knee arthroplasty. Phys
Sportsmed. 2014;42(2):10–8.
20. Lam DM, et al. Efficacy of pregabalin in acute postoperative pain under
different surgical categories: a meta-analysis. Medicine (Baltimore). 2015;
94(46):e1944.
21. Jokela R, et al. Premedication with pregabalin 75 or 150 mg with ibuprofen
to control pain after day-case gynaecological laparoscopic surgery. Br J
Anaesth. 2008;100(6):834–40.
22. Nutthachote P, et al. A randomized, double-blind, placebo-controlled trial of
oral pregabalin for relief of shoulder pain after laparoscopic gynecologic
surgery. J Minim Invasive Gynecol. 2014;21(4):669–73.
23. Mathiesen O, et al. Pregabalin and dexamethasone improves post-operative pain
treatment after tonsillectomy. Acta Anaesthesiol Scand. 2011;55(3):297–305.
24. Gianesello L, et al. Perioperative pregabalin for postoperative pain control
and quality of life after major spinal surgery. J Neurosurg Anesthesiol.
2012;24(2):121–6.
25. Owen RT. Pregabalin: its efficacy, safety and tolerability profile in
generalized anxiety. Drugs Today (Barc). 2007;43(9):601–10.
26. Hwang SH, et al. The efficacy of gabapentin/pregabalin in improving pain
after tonsillectomy: a meta-analysis. Laryngoscope. 2016;126(2):357–66.
27. Busch CA, et al. Efficacy of periarticular multimodal drug injection in total knee
arthroplasty. A randomized trial. J Bone Joint Surg Am. 2006;88(5):959–63.
28. Colwell CJ, Morris BA. The influence of continuous passive motion on the
results of total knee arthroplasty. Clin Orthop Relat Res. 1992;276:225–8.
29. Worland RL, et al. Home continuous passive motion machine versus
professional physical therapy following total knee replacement. J
Arthroplasty. 1998;13(7):784–7.
30. Grant MC, et al. The effect of preoperative pregabalin on postoperative
nausea and vomiting: a meta-analysis. Anesth Analg. 2016;123(5):1100–7.
31. Savk E. Neurologic itch management. Curr Probl Dermatol. 2016;50:116–23.
32. Griffin E, Brown JN. Pregabalin for the treatment of restless legs syndrome.
Ann Pharmacother. 2016;50(7):586–91.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Li et al. Journal of Orthopaedic Surgery and Research  (2017) 12:49 Page 10 of 10
